InsiderSignal.AI

InsiderSignal.ai

ALNY - Alnylam Pharmaceuticals, Inc.

Insider Sale by Fitzgerald Kevin Joseph (CSO, EVP, Head of Research)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Fitzgerald Kevin Joseph, serving as CSO, EVP, Head of Research at Alnylam Pharmaceuticals, Inc. (ALNY), sold 3,250 shares at $323.62 per share, for a total transaction value of $1,051,773.00. Following this transaction, Fitzgerald Kevin Joseph now holds 22,397 shares of ALNY.

This sale represents a 13.00% decrease in Fitzgerald Kevin Joseph's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, March 2, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 4, 2026, 2 days after the trade was made.

Alnylam Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Fitzgerald Kevin Joseph

Fitzgerald Kevin Joseph

CSO, EVP, Head of Research

Kevin Joseph Fitzgerald, Ph.D., is the Executive Vice President, Chief Scientific Officer, and Head of Early Research & Early Development at Alnylam Pharmaceuticals, a position he has held since August 2023[[1]](https://fintool.com/app/research/companies/ALNY/people/kevin-fitzgerald). He has been instrumental in building Alnylam's RNAi (RNA interference) research platform since joining the company in 2005, with over two decades of experience spanning foundational drug discovery and translational research roles at Bristol-Myers Squibb prior to his tenure at Alnylam[[1]](https://fintool.com/app/research/companies/ALNY/people/kevin-fitzgerald). Fitzgerald holds more than 50 patents as an inventor and has authored over 50 peer-reviewed publications, establishing himself as a leading voice in RNAi therapeutic development[[1]](https://fintool.com/app/research/companies/ALNY/people/kevin-fitzgerald). He also serves as a director of Ovid Therapeutics Inc.[[1]](https://fintool.com/app/research/companies/ALNY/people/kevin-fitzgerald) Under Fitzgerald's scientific leadership, Alnylam achieved significant milestones in 2024, including positive Phase 3 results for vutrisiran in ATTR cardiomyopathy, orphan drug designation for nucresiran, and initiation of multiple clinical trials for pipeline candidates targeting conditions such as Huntington's disease, bleeding disorders, and Alzheimer's disease[[1]](https://fintool.com/app/research/companies/ALNY/people/kevin-fitzgerald). These achievements contributed to the company's global net product revenues growing 33% year-over-year, with strong shareholder returns including a three-year total shareholder return of 38.76% (2022–2024)[[1]](https://fintool.com/app/research/companies/ALNY/people/kevin-fitzgerald). At age 57, Fitzgerald maintains an active role in guiding Alnylam's early-stage research programs while overseeing the development of marketed and investigational RNAi-based therapeutics[[1]](https://fintool.com/app/research/companies/ALNY/people/kevin-fitzgerald).

View full insider profile →

Trade Price

$323.62

Quantity

3,250

Total Value

$1,051,773.00

Shares Owned

22,397

Trade Date

Monday, March 2, 2026

3 days ago

SEC Filing Date

Wednesday, March 4, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Alnylam Pharmaceuticals, Inc.

Company Overview

No company information available
View news mentioning ALNY

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4500354

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime